Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Prostate01: ifinatamab deruxtecan versus docetaxel in first-line metastatic castration-resistant prostate cancer
CTR20252497Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ifinatamab deruxtecan in prostate cancer (PCa), sponsored by Merck & Co.. Started Sep 2025; status: active.
02
Drugs
ifinatamab deruxtecan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20252497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252497.